| 19.37 1.49 (8.33%) | 07-17 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 24.11 | 1-year : | 28.17 |
| Resists | First : | 20.64 | Second : | 24.11 |
| Pivot price | 18.85 |
|||
| Supports | First : | 15.92 |
Second : | 13 |
| MAs | MA(5) : | 18.62 |
MA(20) : | 18.42 |
| MA(100) : | 16.2 |
MA(250) : | 14.9 |
|
| MACD | MACD : | 0.7 |
Signal : | 0.8  |
| %K %D | K(14,3) : | 40 |
D(3) : | 41.5 |
| RSI | RSI(14): 58.4 |
|||
| 52-week | High : | 24.27 | Low : | 6.21 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ AVTX ] has closed below upper band by 31.8%. Bollinger Bands are 54.2% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 4 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 19.5 - 19.63 | 19.63 - 19.74 |
| Low: | 17.3 - 17.44 | 17.44 - 17.54 |
| Close: | 19.18 - 19.41 | 19.41 - 19.58 |
Avalo Therapeutics, Inc. is a precision medicine company in the clinical development phase, dedicated to identifying, advancing, and marketing specialized treatments for patients experiencing critical unmet medical needs across the fields of immunology, immuno-oncology, and rare genetic disorders. Among its key pipeline assets is AVTX-002, a fully human monoclonal antibody designed to inhibit LIGHT. This drug is currently undergoing Phase II clinical trials for non-eosinophilic asthma and inflammatory bowel diseases, specifically moderate to severe Crohn's disease and ulcerative colitis. Furthermore, AVTX-002 is also being investigated in Phase III for its potential to treat acute respiratory distress syndrome caused by COVID-19. The company is also advancing AVTX-007, a fully human monoclonal antibody targeting IL-18, which is progressing through Phase I clinical studies for Still's disease, encompassing both adult-onset Still's disease and systemic juvenile idiopathic arthritis. Avalo's late-stage pipeline includes two products addressing rare genetic conditions, both in Phase III clinical trials: AVTX-801, a D-galactose substrate replacement therapy for phosphoglucomutase 1 deficiency (PGM1), also known as PGM1-CDG; and AVTX-803, an L-fucose substrate replacement therapy intended for LADII, medically referred to as SLC35C1-CDG. Established in 2011, the corporation initially operated as Cerecor Inc. before rebranding as Avalo Therapeutics, Inc. in August 2021. Its main operations are situated in Rockville, Maryland.
Fri, 17 Jul 2026
Avalo Therapeutics (NASDAQ: AVTX) files to register 128,189 shares for selling stockholders - Stock Titan
Tue, 07 Jul 2026
Avalo Therapeutics sets one-on-one investor meetings at Leerink Forum - Stock Titan
Mon, 29 Jun 2026
Avalo Therapeutics (AVTX) Is Up 12.9% After Broad Russell Index Additions - What's Changed - Yahoo Finance
Fri, 26 Jun 2026
AVTX Forecast — Price Target — Prediction for 2027 - TradingView
Tue, 23 Jun 2026
Why Avalo Therapeutics, Inc. (AVTX) Is Among the Best Low Priced Stocks to Get Rich in 2026 - Yahoo Finance
Tue, 16 Jun 2026
Avalo develops longer-lasting antibody to enable less frequent dosing - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 53 (M) |
| Held by Insiders | 4.027e+007 (%) |
| Held by Institutions | 1.7 (%) |
| Shares Short | 6,380 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -7.893e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -134 % |
| Return on Assets (ttm) | 164.3 % |
| Return on Equity (ttm) | -41.5 % |
| Qtrly Rev. Growth | 59000 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | -112.36 |
| EBITDA (p.s.) | -5.00253e+007 |
| Qtrly Earnings Growth | -5.4 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -60 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.18 |
| Price to Cash Flow | 5.52 |
| Dividend | 0 |
| Forward Dividend | 1.231e+007 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|